Bundibugyo Ebola

Manufactured by BioFire Defense, a bioMérieux subsidiary, the panel tests for 16 pathogens from a single whole blood sample in approximately one hour.

Nigeria is the fifth country to detect the virus since the Democratic Republic of the Congo (DRC) declared an outbreak on 15 May 2026.

The regulations require anyone who knows or reasonably suspects that a person has Ebola, or has died from the disease, to notify a medical officer of health, the nearest health facility or a national government administrative officer immediately.

The trials will advance the evaluation of the two candidates against the Bundibugyo virus, a species distinct from the Zaire Ebola virus targeted by the widely used Ervebo vaccine.

Africa CDC will participate in the meeting, with Director General H.E. Dr Jean Kaseya representing the African Union’s 55 Member States and the continent’s 1.5 billion people.

The allocation forms part of an initial release of 70,000 Ervebo doses to the Democratic Republic of the Congo (DRC).

As of September 2, the outbreak had recorded 6,342 cases and 3,072 deaths, making it the second largest Ebola outbreak ever reported in the country and the fastest growing to date.

The guidance recommends that Ervebo® should currently be used against Bundibugyo virus (BDBV) only within a research protocol.

The mobile laboratory forms part of efforts to strengthen Uganda’s public health emergency preparedness following lessons from recent Ebola outbreaks.